The Ofev Patent Thicket: Patents expiring in 2026
With an average life expectancy of 3-5 years after diagnosis, Pulmonary fibrosis highlights an urgent need for innovative therapeutic interventions. That’s where medications like Ofev have emerged as a transformative solution. Ofev is the trade name for Nintedanib by Boehringer Ingelheim. It is a Tyrosine Kinase Inhibitor (TKI) or anti-fibrotic agent used to treat non-small […]
The Trajenta Patent Thicket: Patents expiring in 2025
Trajenta, known for its effective glycemic control without weight gain, is a key player in the diabetes medication sector. This critical medication, known generically as Linagliptin, is on the brink of its patent expiration, presenting an opportunity for generic drug manufacturers to introduce their own generic versions. Manufactured by Boehringer Ingelheim, Trajenta® is an oral […]
Recent Patent Oppositions in the Pharmaceutical Industry
The European Patent Office (EPO) receives more than 2000 oppositions each year, directly impacting the future success and exclusivity of pharmaceutical products. Monitoring the outcomes of these oppositions is crucial as it assists in developing effective strategies for launching generic versions of drugs. Moreover, it aids in identifying competitors that may be eating into market […]
Understanding the Farxiga®/Forxiga® Patent Thicket: What’s Changing in 2025
While numerous drugs for diabetes are available in the market, many come with undesirable side effects such as weight gain, hypoglycemia, and hypertension. However, a game-changing solution has been introduced in the form of Farxiga®/Forxiga®. Farxiga®/Forxiga® is the trade name for Dapagliflozin, by AstraZeneca. It is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, representing a novel […]
Arthritis Drug Patents Expiring 2024 – 2028
The arthritis treatment industry is characterized by its intense competitiveness, driving companies to invest significantly in research and development to secure leading arthritis drug patents. Consequently, the expiration of patents for this disease creates significant opportunities for companies specializing in generic medications. A notable example of the market dynamics in this industry is the case […]
The Mounjaro Patent Thicket: Patents expiring in 2036
More than 500 million people around the world are affected by diabetes, and this issue is intensified by a surging obesity crisis, particularly in wealthier nations. In such a crisis, drugs like Mounjaro represent a highly lucrative opportunity for generic drugmakers to address the escalating medical demand on a global scale. For the uninitiated, Mounajro® […]
Cancer Drug Patents Expiring 2024-2028
The fiercely competitive nature of the oncology industry makes the companies invest heavily in research and development to bring in top cancer-treating drug patents. Consequently, the expiration of patents for cancer drugs creates significant opportunities for companies specializing in generic medications. Identifying these patents can help enterprises expand and diversify their generic drug portfolios. This […]
30 Diabetes Drug Patents Expiring from 2024 till 2028 – GreyB
Given the competitive nature of the pharmaceutical domain, the expiration of drug patents presents significant opportunities, particularly for companies specializing in generic medications. Pharmaceutical companies seeking to expand or diversify their generic drug portfolios would find this list of great value in identifying diabetes drug patents that will expire between 2024 and 2028. By utilizing […]
Does the FDA’s warning mark an end to Ozempic?
The recent FDA controversy around Novo Nordisk’s Ozempic has brought many eyes to the drug. For the uninitiated, Ozempic (semaglutide) is an anti-obesity medication for long-term weight management. However, an FDA-approved label was recently updated to warn of potential serious intestinal side effects like obstruction or blockage. In this study, we see how this FDA […]
Lead the generic drug market with this one effective strategy
Closely monitoring the patent expirations of well-known branded drugs, such as Abilify for schizophrenia and Abaraxane for cancer treatment, is essential. This practice of monitoring patents can give generic drug makers a significant competitive edge, ultimately granting them an advantage in the generic drug market. As top blockbuster drugs approach patent expiration, strategic ANDA filings […]
Tap Into The Loteprednol Etabonate Generic Drug’s Transformational Potential
In 2020, the FDA approved loteprednol etabonate ophthalmic suspension 0.25% (Eysuvis, Kala Pharmaceuticals Inc.) for treating dry eye disease. As one of the most common ocular surface disorders, dry eye disease impacts 16.7 million to 50.2 million people in the U.S.A. Additionally, this disease costs over $55.4 billion to the economy each year. Eysuvis ophthalmic […]
Why is drug exclusivity knowledge crucial for generic drug launches?
Monitoring the drug exclusivity expiration timelines is just as important as patent expiration date when identifying opportunities and timing generic launches. Having access to detailed exclusivity data can reveal openings for generic entry even when patents are still active. As top blockbuster drugs approach patent expiration, strategic ANDA filings are critical to secure early mover […]
Top 20 Patent Buyers Of Cancer Curing Technologies
During the second quarter of 2023, there was a 7% increase in patent applications for immuno-oncology compared to the previous quarter, indicating a dynamic transformation in the oncology landscape. Interestingly, along with patent filing, we also saw companies actively acquiring patents in the domain. Thus confirming that it’s not just the number of patent filings […]
First to get ANDA approval for a generic drug
With companies filing for ANDAs, the global prescribed generics sales are expected to reach nearly 100 billion U.S. dollars by 2026. One example of this is Rexulti – a prescription medicine used along with antidepressant medicines to treat major depressive disorder (MDD) in adults. Zydus Pharmaceuticals stood out by being among the first applicants to submit […]
What’s next for Humira Biosimilars as the drug’s exclusivity ends?
Are you familiar with Humira? The first fully lab-made immune protein approved by the US Food and Drug Administration (FDA) for various treatments. In case you aren’t, Humira is a blockbuster anti-inflammatory drug made by AbbVie, which is losing its market exclusivity in 2023. The drug treats conditions like rheumatoid arthritis, psoriasis, Crohn’s disease, and […]
The Stelara Patent Thicket: Patents Expiring in 2023
If Drug research and development is your bread and butter, you must be familiar with the wonders of Stelara. For the uninitiated, Stelara is the brand name of the drug Ustekinumab, which is developed by Janssen Pharmaceuticals, a subsidiary of J&J. It is used for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis, and […]
